• Bedwell Home Page
  • Bedwell Lab Personnel
  • Bedwell Lab Alumni
  • Bedwell NIH Biosketch
  • Publications & Recognition
  • Publications on PubMed
  • Bedwell Lab Awards
  • Meetings & Schedules
  • Courses & Notes
  • About UAB
  • Bedwell Departmental Page
  • Bedwell School of Medicine Page
  • Bedwell LinkedIn Profile

  • Welcome to the laboratory of David M. Bedwell, Ph.D., in the Department of Microbiology at the University of Alabama at Birmingham. Our research uses molecular biological approaches to gain a better understanding of complex processes shared by all eukaryotic cells. While we primarily utilize a yeast experimental system, we also frequently carry out complementary studies using mammalian systems. There are currently two major projects under investigation in the lab.

    A major objective of research in Dr. Bedwell’s lab is to understand the mechanistic details of translation termination in eukaryotes. Besides the release factors eRF1 and eRF3, many other cellular components influence the process of translation termination. Surprisingly sophisticated cellular machineries also regulate the abundance of mRNAs based on the location of stop codons. We are using a combination of genetics, biochemistry, and cell biology in a yeast experimental system to better understand the molecular details of how these processes are carried out.

    We are also investigating whether pharmacological agents can be used to suppress nonsense mutations that cause genetic diseases.  First, we are exploring whether this novel therapeutic approach can benefit patients with cystic fibrosis (CF).  CF is caused by mutations in the CFTR gene (which corresponds to the mouse Cftr gene).  We have published several papers demonstrating that drugs can suppress nonsense mutations in the CFTR gene in various CF experimental systems, including cultured CF cell lines and a CF mouse expressing a human CFTR-G542X transgene.  Most recently, we have constructed a new Cftr-G542X knock-in mouse model to explore this approach in a more physiologically relevant context.

    We are also investigating whether this therapeutic approach can benefit patients with the lysosomal storage disease mucopolysaccharidosis type I-H (MPS I-H, or Hurler syndrome).  MPS I-H is caused by mutations in the human IDUA gene (which corresponds to the mouse Idua gene).  We have constructed a Idua-W392X knock-in mouse and have preliminary evidence that nonsense suppression can partially alleviate the primary biochemical defect that causes this devastating genetic disease.

    Finally, the availability of these knock-in mouse models for CF and MPS I-H will allow us to explore whether the suppression of Nonsense-Mediated mRNA Decay (NMD) can further enhance the therapeutic effect provided by nonsense suppression agents.  It is hoped that either nonsense suppression alone or in combination with NMD suppression will ultimately provide a therapeutic benefit for a broad range of human genetic diseases caused by nonsense mutations.